Nexalin Technology Inc. (NASDAQ:NXL) shares soared 84.4% in premarket trading Wednesday after the company released positive clinical results demonstrating that its non-invasive brain stimulation therapy improved cognitive function in patients with mild Alzheimer’s disease.
The study, published in Radiology, evaluated Nexalin’s proprietary 15 milliamp Gen-2 Deep Intracranial Frequency Stimulation (DIFS) system in a randomized, sham-controlled trial. Patients treated with the device showed statistically significant improvements in Mini-Mental State Examination (MMSE) scores compared with the placebo group.
Functional MRI imaging revealed enhanced connectivity between the hippocampus and cortical regions associated with memory and executive function. Researchers also observed increased network integration across broader cognitive pathways often impaired in Alzheimer’s patients.
“The results of this study represent a significant milestone for Nexalin’s technology platform,” said Mark White, CEO of Nexalin. “The data clearly supports our belief that Nexalin’s non-invasive deep, frequency-specific neurostimulation can meaningfully improve cognitive performance in patients with Alzheimer’s disease.”
The company highlighted that its Gen-2 SYNC 15 mA DIFS device is already approved for use in China to treat depression and insomnia, and in Brazil and Oman for anxiety, depression, and insomnia. Nexalin plans to pursue additional regulatory clearances, including from the U.S. FDA, to expand clinical applications of the therapy.
Importantly, no adverse events were reported during the study, reinforcing the safety and tolerability of Nexalin’s technology.
Nexalin Technology stock price
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.